Professor Sun Myint
Clatterbridge Cancer Centre (Private Clinic)
Professor Sun Myint introduced Papillon in 1993 and established the first facility in the UK at Clatterbridge Cancer Centre. He has now treated over 1600 patients with Papillon which is the world largest cohort treated by non-surgical method. He collaborated with his mentor Prof Jean Pierre Gerard (Nice) and Ariane a British company to produce a new contact X-ray machine. Since 2009 he used the first prototype Papillon 50. He is now working closely with Ariane to produce a second generation Papillon Plus machine which can treat other tumour sites such as breast, skin, eye, intra oral, intra vagina and intra operative radiation therapy.
NICE has now approved the Papillon treatment for rectal cancer in patients not suitable for surgery (IPG 532). For his contributions to oncology, he was awarded Honorary Professor by University of Liverpool in 2012. He led the UK Papillon team which won the prestigious BMJ award for ‘Cancer team of the year’ in May 2018.
Rectal cancer- Do patients have a choice?
Each year 12,000 patients are diagnosed with rectal cancer in the UK. The standard of care is radical surgery. Not all patients are suitable for surgery due to advancing age and their comorbidities. The mortality and morbidity is high following surgery in elderly patients. There is increase in ageing population in the UK. Contact X-ray brachytherapy[CXB] (Papillon) will be discuss as an alternative non-surgical treatment option for patients not suitable for surgery.
EVEN MORE SEMINARS
Joanne Edwards University of Glasgow
Role of IKK alpha in Breast Cancer
Dr. Anna ME Bruynzeel Amsterdam UMC (formerly VUmc)
MR Guided Adaptive Radiation Therapy; three years of clinical experience at VUmc
Professor Zoë Winters University College London
Is breast conserving surgery a future treatment for multiple ipsilateral breast cancers?
Dr. Petr Kavan McGill Young Adults Oncology Program
Comparing Clinical Characteristics and Outcomes of Young-onset and Late-Onset Colorectal Cancer
Stuart Dollow Vermilion Life Sciences Ltd
Reengineering Medicines Development